insider buiying, story stock (biotech exploring extended applications for oxytocin (aka love hormone)
downside is pending offering by selling shareholders. i wonder if it will spike in advance of this so that offering can be done at reasonable price. i'm nibbling at current levels. would like more at lower levels
I bought a bit. The situation today with insiders is far different than in 2009 when it was possible to find many good companies of all caps with buying. Its harder to find gems today. Aside from TGC, JSDA and TGC and GKNT and a few others, much of my buying has been depressed biotechs/medical device cos with insider buying. Most of these companies have no earnings and are relying upon future approval of drugs.